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Exploring the Effect of G6PC2 Single Nucleotide Polymorphisms on Enzyme Activity and Human
Health
Lauren P. Muenchow (University of Texas-Rio Grande Valley School of Medicine), Karin J Bosma, James
K. Oeser, and Richard M. O’Brien
Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville,
Tennessee
G6PC2 encodes a glucose-6-phosphatase catalytic subunit that is highly expressed in pancreatic islet
beta cells. Genome wide association studies (GWAS) have shown that single nucleotide polymorphisms
(SNPs) in the G6PC2 gene are associated with variations in fasting blood glucose (FBG), a parameter
linked with risk for type 2 diabetes (T2D). Studies in mice have complemented these GWAS data by
showing that deletion of G6pc2 abolishes islet glucose-6-phosphatase activity and lowers FBG. We
hypothesize that G6pc2 forms a substrate cycle with glucokinase that determines the sensitivity of
glucose-stimulated insulin secretion (GSIS) to glucose. In support of this hypothesis we have previously
shown that deletion of G6pc2 enhances GSIS at sub-maximal glucose concentrations and abolishes
glucose cycling in isolated islets. More recently we have demonstrated that deletion of G6pc2 enhances
glycolysis in isolated mouse islets, and that high rates of glucose cycling are also detected in human
islets. Our broad hypothesis is that the results of these studies will strongly suggest that G6PC2
inhibition should be considered as a novel therapeutic strategy for lowering FBG and thereby
preventing T2D. To extend these observations we have developed a novel intact cell assay for G6PC2
activity. This assay relies on the observation that CREB and ChREBP bound to the rat G6PC1 promoter
are highly glucose responsive in the rat islet-derived 832/13 cell line and the fact that endogenous
G6PC2 is absent. In the presence of catalytically-dead G6PC2, glucose stimulates G6PC1-luciferase
fusion gene expression. However, this induction is blunted in the presence of wild type G6PC2. We are
using this assay to determine the effect of non-synonymous G6PC2 SNPs on G6PC2 activity and then
examining the association between SNPs that markedly affect G6PC2 activity with their effects on
human health as assessed using Vanderbilt’s BioVU biobank. These data will reveal whether SNPs in
G6PC2 are associated with only altered FBG or whether G6PC2 affects other aspects of human health.

